Isomorphic Labs faces delivery test in AI drug discovery push

Isomorphic Labs, Alphabet's AI drug discovery unit, is under scrutiny over whether its computational platform can produce viable medicines. The piece questions the firm's ability to translate AI breakthroughs into clinical candidates, a key uncertainty for the sector. This matters as AI-driven pharma bets hinge on tangible pipeline progress.